About sentinelone inc - S
S At a Glance
Phone | 1-855-868-3733 | Revenue | 621.15M | |
Industry | Packaged Software | Net Income | -338,693,000.00 | |
Sector | Technology Services | 2024 Sales Growth | 47.13% | |
Fiscal Year-end | 01 / 2025 | Employees | 2,300 | |
View SEC Filings |
S Valuation
P/E Current | N/A |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | N/A |
Price to Sales Ratio | 12.725 |
Price to Book Ratio | 5.123 |
Price to Cash Flow Ratio | N/A |
Enterprise Value to EBITDA | -20.852 |
Enterprise Value to Sales | 11.172 |
Total Debt to Enterprise Value | 0.003 |
S Efficiency
Revenue/Employee | 270,066.957 |
Income Per Employee | -147,257.826 |
Receivables Turnover | 2.898 |
Total Asset Turnover | 0.271 |
S Liquidity
Current Ratio | 2.107 |
Quick Ratio | 2.107 |
Cash Ratio | 1.673 |
S Profitability
Gross Margin | 69.854 |
Operating Margin | -59.842 |
Pretax Margin | -53.583 |
Net Margin | -54.526 |
Return on Assets | -14.789 |
Return on Equity | -20.838 |
Return on Total Capital | -20.946 |
Return on Invested Capital | -20.576 |
S Capital Structure
Total Debt to Total Equity | 1.438 |
Total Debt to Total Capital | 1.418 |
Total Debt to Total Assets | 0.988 |
Long-Term Debt to Equity | 1.144 |
Long-Term Debt to Total Capital | 1.128 |
Sentinelone Inc in the News
Media, Biden admin called out for 'amazing strategy' of claiming Americans don't understand economy
Journalist Matt Taibbi sounds off on the media and the White House "trying to tell people" that their perceptions of inflation and the economy are "irrational" or "partisan."
Running low on Ozempic or another weight loss drug? A new tracker can help
Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.
Warren Buffett's favorite ETFs
While Warren Buffett is the largest investor in several of America's biggest companies, he also allocates some money into two ETFs that track the S&P 500, the broadest measure of U.S. stocks.
Nestlé launches food line targeting Ozempic, other weight-loss drug users
Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.
Vanguard names BlackRock veteran as CEO: WSJ
Vanguard, the firm founded by John C. Bogle, may soon appoint the first outsider to be CEO in its 50-year history.
25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says
Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week.
Start investing today: 5 steps to take right now
For those new to investing, getting started isn't complicated. We breakdown how to get in the game in five easy steps.
Janet Yellen walks back Biden's comments US taxpayers on hook for Baltimore bridge collapse
Treasury Secretary Janet Yellen appeared to walk back comments from President Biden that American taxpayers would foot the bill for the Francis Scott Key Bridge collapse in Baltimore.
Average Wall Street bonus dipped to $176,500 last year
Wall Street's average yearly cash bonuses declined by 2% in 2023 to $176,500, down from $180,000 the year before despite an increase in industry profits.
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug
Wegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.